Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026)

Mineralys Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $392000.0 in Q1 2026.

• Quarterly Non-Current Assets fell 9.89% year-over-year to $392000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 29.06% YoY) and the FY2025 annual result came in at $420000.0, down 23.91% from the prior year.
• Non-Current Assets retreated to $392000.0 in Q1 2026 per MLYS's latest filing, from $420000.0 in the prior quarter.
• Over five years, Non-Current Assets peaked at $31.2 million in Q1 2023 and troughed at $151000.0 in Q3 2025.
• A 5-year average of $5.2 million and a median of $506000.0 in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 55.3% in 2023, then sank 98.62% in 2024.
• Over 5 years, Non-Current Assets stood at $1.6 million in 2022, then soared by 55.3% to $2.5 million in 2023, then tumbled by 78.21% to $552000.0 in 2024, then fell by 23.91% to $420000.0 in 2025, then slipped by 6.67% to $392000.0 in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $392000.0, $420000.0, and $151000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.